11 years of work culminates for Orphazyme: "Lots of things are starting to fall into place"
Lots of things are happening for Orphazyme at the moment, and Financial Director Anders Vadsholt's optimism after the company sent its drug arimoclomol for FDA approval is clear to see.
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT
Friday was a happy day for biotech company Orphazyme, which announced that it had sent its drug arimoclomol for approval at the FDA.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
